Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge

Autor: Ignacio Romero, Gabriella Ferrandina, Nicoletta Colombo, Anne Claire Hardy-Bessard, Christian Marth
Přispěvatelé: Colombo, N, Hardy-Bessard, A, Ferrandina, G, Marth, C, Romero, I
Rok vydání: 2016
Předmět:
0301 basic medicine
Oncology
medicine.medical_specialty
platinum sensitive
endocrine system diseases
chemistry.chemical_element
Platinum Compounds
Dioxoles
Polyethylene Glycols
Carboplatin
Pegylated Liposomal Doxorubicin
Drug Hypersensitivity
03 medical and health sciences
chemistry.chemical_compound
pegylated liposomal doxorubicin
0302 clinical medicine
Tetrahydroisoquinolines
recurrent ovarian cancer
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Humans
Medicine
Pharmacology (medical)
Trabectedin
Ovarian Neoplasms
business.industry
sequence effect
medicine.disease
female genital diseases and pregnancy complications
Surgery
Survival Rate
Regimen
Treatment Outcome
030104 developmental biology
chemistry
Doxorubicin
Recurrent Ovarian Cancer
030220 oncology & carcinogenesis
trabectedin
Female
Platinum sensitive
Neoplasm Recurrence
Local
hypersensitivity
business
Ovarian cancer
Platinum
medicine.drug
Zdroj: Expert Review of Anticancer Therapy. 16:11-19
ISSN: 1744-8328
1473-7140
Popis: Introduction: As most patients with ovarian cancer experience multiple remissions and relapses, oncologists must prepare ahead for long-term treatment. While platinum-based regimens are standard of care for platinum-sensitive recurrence, there are circumstances in which platinum rechallenge is not the best approach. These situations include patients with limited sensitivity to platinum; patients with residual toxicity from previous platinum therapy; and patients at risk of developing hypersensitivity reactions. An alternative regimen for these patients is the non-platinum combination of trabectedin + pegylated liposomal doxorubicin (PLD). Areas covered: In this review, case studies are presented to illustrate how careful strategic planning, in terms of therapeutic choices and optimal sequencing, can achieve good outcomes in difficult-to-treat patients. Expert commentary: Advantages with use of trabectedin + PLD in selected patients with platinum-sensitive recurrent ovarian cancer include additional time to recover from platinum-related toxicities, avoidance of hypersensitivity reactions, and the ‘sequence effect’ by which trabectedin may enhance response to next platinum and prolong survival.
Databáze: OpenAIRE
Externí odkaz: